People with OCD have six times higher Immuno-moodulin (Imood) expression that those without the disorder. Blocking Imood with the aid of an antibody reduced OCD-like behaviors in mouse models within a couple of days following treatment.
Johns Hopkins University researchers propose using antibodies from the plasma or serum of those who have recovered from COVID-19 to help boost the immunity of newly infected patients and for those at risk of contracting the disease. Researchers say the antibodies may bind to and neutralize SARS-CoV-2. The technique has been proven successful in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic.
S309, a neutralizing antibody first identified in blood samples from a patient who recovered from SARS in 2003, shows promise for the treatment of COVID-19.
A newly developed antibody has shown to trigger a meaningful reduction of amyloid beta in patients with early stage Alzheimer's disease.
Embryonic damage caused by autoantibodies is implicated in a range of behavioral and psychological disorders, including schizophrenia, autism, and ADHD.
Structural mapping of both SARS and SARS-CoV-2, the virus that causes COVID-19, reveals an almost identical site on both coronaviruses to which the CR3022 antibody binds. This suggests a functionally important and vulnerable site for this family of coronaviruses.
Using computational methods, researchers created artificial proteins that triggered immune responses and produced infection specific antibodies. The findings indicate it will be possible to design vaccines that contain artificial antibodies, expediting the process of vaccine development.
Researchers have developed a novel antibody strategy to prevent the association between a harmless protein and a disease mediator that could lead to sepsis, and ultimately death. The findings could help to prevent sepsis induced by COVID-19 infections.
While the amount of antibodies generated varies widely in patients who have recovered from coronavirus, most people generate at least some antibodies which are intrinsically capable of neutralizing the SARS-CoV-2 virus.